CUVL Clinuvel Pharmaceuticals Ltd Annual reports only
American Depositary Receipts · Nasdaq · SEC CIK 1290877 · Fiscal year ends 06/30
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY5.2%
TTM net income YoY0.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin82.9%
Operating margin43.4%
Net margin36.0%
FCF margin18.4%
EBITDA margin44.0%
Returns
ROE13.4%
ROA12.2%
ROIC (approx.)12.6%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio14.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio5.4%
Payout ratio7.2%
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | $64.32M | $61.12M | $57.91M |
| Cost of revenue | $10.98M | $11.51M | $10.74M |
| Gross profit | $53.34M | $49.61M | $47.17M |
| R&D expense | $12.23M | $13.22M | $9.99M |
| SG&A expense | $7.38M | $6.68M | $6.81M |
| Operating income | $27.92M | $26.52M | $28.53M |
| Pretax income | $32.72M | $33.09M | $33.22M |
| Income tax | $9.54M | $9.97M | $9.87M |
| Net income | $23.18M | $23.12M | $23.35M |
| EBITDA | $28.31M | $27.03M | $29.02M |
| EPS (basic) | 0.46 | 0.46 | 0.47 |
| EPS (diluted) | 0.46 | 0.46 | 0.46 |
| Weighted avg. shares (diluted) | 50.75M | 50.38M | 51.03M |
| Banking | |||
| Deposits | $160.10M | $127.46M | — |
| Balance sheet | |||
| Cash & equivalents | $13.91M | $18.06M | — |
| Short-term investments | $160.10M | $127.46M | — |
| Receivables | $16.19M | $17.75M | $17.51M |
| Inventory | $4.76M | $5.73M | — |
| Current assets | $196.53M | $170.70M | — |
| PP&E, net | $5.05M | $4.51M | — |
| Intangibles | $127,892 | $120,331 | — |
| Total assets | $203.98M | $176.74M | — |
| Current liabilities | $13.35M | $17.63M | — |
| Total liabilities | $15.36M | $20.00M | — |
| Shareholders' equity | $188.62M | $156.74M | $135.03M |
| Shares outstanding | 50.43M | 50.12M | — |
| Cash flow statement | |||
| Operating cash flow | $12.91M | $27.30M | $23.75M |
| Capital expenditure | $1.06M | $190,593 | $3.65M |
| Free cash flow | $11.85M | $27.10M | $20.10M |
| Investing cash flow | -$25.64M | -$30.62M | -$19.25M |
| Financing cash flow | -$1.67M | -$1.87M | -$2.09M |
| Depreciation & amortization | $390,345 | $508,875 | $493,710 |
| Stock-based compensation | $1.59M | $1.30M | $4.07M |
| Dividends paid | $1.67M | $1.69M | $1.59M |
| Share buybacks | — | $173,965 | $497,659 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.